Abstract
Hydralazine is the most commonly used antihypertensive agent for patients with severe toxemic states. Its use, however, can produce hypotension and acute uteroplacental insufficiency, resulting in fetal distress. Our review of hospital charts of severely preeclamptic or eclamptic patients observed during a two-year period showed that 24 of 77 patients were treated with hydralazine; the remainder were not. Of those receiving hydralazine, 38% (9/24) were delivered by cesarean section because of fetal distress, as compared to 9% (5/53) of those not receiving hydralazine (P less than .01). Of patients whose hydralazine therapy was inappropriate, 82% (9/11) incurred fetal distress versus 38% (5/13) when hydralazine was appropriately administered (P less than .05). In patients receiving hydralazine, fetal distress is in part the consequence of the severity of the disease, but excess use of antihypertensive agents appears to increase this risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
